This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 23N
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Competidores de Nuvo Pharmaceuticals Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.90 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.34 |
| Beta | 0.78 |
| 1 Month Change | -0.55% |
| 3 Month Change | 109.30% |
| 1 Year Change | -3.23% |
| 3 Year Change | 97.37% |
| 5 Year Change | n/a |
| Change since IPO | -94.67% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 23N | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | -0.6% | 1.6% | -0.3% |
| 1Y | -3.2% | -26.4% | 2.8% |
Rentabilidad vs. Industria: 23N exceeded the German Pharmaceuticals industry which returned -8.9% over the past year.
Rentabilidad vs. Mercado: 23N exceeded the German Market which returned -13.7% over the past year.
Volatilidad de los precios
| 23N volatility | |
|---|---|
| 23N Average Weekly Movement | 30.2% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 23N's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 23N's weekly volatility has increased from 23% to 30% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1983 | 101 | Jesse Ledger | www.miravohealthcare.com |
Resumen de fundamentos de Nuvo Pharmaceuticals Inc.
| Estadísticas fundamentales de 23N | |
|---|---|
| Capitalización bursátil | €10.56m |
| Beneficios(TTM) | €10.42m |
| Ingresos (TTM) | €49.72m |
1.0x
Ratio precio-beneficio (PE)0.2x
Ratio precio-ventas (PS)¿Está 23N sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 23N | |
|---|---|
| Ingresos | CA$72.42m |
| Coste de los ingresos | CA$27.36m |
| Beneficio bruto | CA$45.06m |
| Otros gastos | CA$29.89m |
| Beneficios | CA$15.17m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.33 |
| Margen bruto | 62.22% |
| Margen de beneficio neto | 20.95% |
| Ratio deuda/patrimonio | 1,149.7% |
¿Cómo se ha desempeñado 23N a largo plazo?
Ver rendimiento histórico y comparativa